Skip to main content

Breast Cancer Research and Treatment

Ausgabe 1/2010

Inhalt (37 Artikel)

Review

Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer

Rob Riemsma, C. A. Forbes, A. Kessels, K. Lykopoulos, M. M. Amonkar, D. W. Rea, J. Kleijnen

Preclinical study

The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study

Felice A. Tager, Paula S. McKinley, Freya R. Schnabel, Mahmoud El-Tamer, Ying Keun K. Cheung, Yixin Fang, Claire R. Golden, Margery E. Frosch, Ulya Habif, Margaret M. Mulligan, Ivy S. Chen, Dawn L. Hershman

Preclinical Study

GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer

Hugo Arias-Pulido, Melanie Royce, Yun Gong, Nancy Joste, Lesley Lomo, Sang-Joon Lee, Nabila Chaher, Claire Verschraegen, Juanita Lara, Eric R. Prossnitz, Massimo Cristofanilli

Preclinical Study

Gli1 promotes cell survival and is predictive of a poor outcome in ERα-negative breast cancer

Lusheng Xu, Yeon-Jin Kwon, Natalya Frolova, Adam D. Steg, Kun Yuan, Martin R. Johnson, William E. Grizzle, Renee A. Desmond, Andra R. Frost

Preclinical study

A unique proteolytic fragment of alpha1-antitrypsin is elevated in ductal fluid of breast cancer patient

Junma Zhou, Bruce Trock, Theodore N. Tsangaris, Neil B. Friedman, Deanna Shapiro, Michelle Brotzman, Yee Chan-Li, Daniel W. Chan, Jinong Li

Preclinical study

Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells

Atanas Ignatov, Tanja Ignatov, Albert Roessner, Serban Dan Costa, Thomas Kalinski

Preclinical study

Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment

Erika Resetkova, Jorge S. Reis-Filho, Rohit K. Jain, Rutika Mehta, Mangesh A. Thorat, Harikrishna Nakshatri, Sunil Badve

Invited Commentary

Is ALDH1 a good method for definition of breast cancer stem cells?

Veronique Neumeister, David Rimm

Preclinical Study

Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer

Brenda Cohen, Mamiko Shimizu, Julia Izrailit, Nancy F. L. Ng, Yuri Buchman, James G. Pan, Judy Dering, Michael Reedijk

Preclinical study

Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue

In Hae Park, Youngmee Kwon, Jae Y. Ro, Keun Seok Lee, Jungsil Ro

Preclinical study

Five common single nucleotide polymorphisms in the PALB2 gene and susceptibility to breast cancer in eastern Chinese population

A-Yong Cao, Ke-Da Yu, Wen-Jin Yin, Wei Jin, Gen-Hong Di, Zhen-Zhou Shen, Zhi-Ming Shao

Preclinical Study

Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells

Tisheeka R. Graham, Rami Yacoub, LaTonia Taliaferro-Smith, Adeboye O. Osunkoya, Valerie A. Odero-Marah, Tongrui Liu, K. Sean Kimbro, Dipali Sharma, Ruth M. O’Regan

Clinical trial

Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer

Miguel Martín, Álvaro Rodríguez-Lescure, Amparo Ruiz, Emilio Alba, Lourdes Calvo, Manuel Ruiz-Borrego, Ana Santaballa, César A. Rodríguez, Carmen Crespo, Mar Abad, Severina Domínguez, Jesús Florián, Cristina Llorca, Miguel Méndez, María Godes, Ricardo Cubedo, Adolfo Murias, Norberto Batista, María José García, Rosalía Caballero, Enrique de Álava

Invited Commentary

Adjuvant chemotherapy is not for everyone

I. Craig Henderson

Clinical trial

CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D

Katrín Á. Gunnarsdóttir, Maj-Britt Jensen, David Zahrieh, Richard D. Gelber, Ann Knoop, Marco Bonetti, Henning Mouridsen, Bent Ejlertsen

Invited Commentary

Re-searching anthracycline therapy

Catherine Oakman, Erica Moretti, Angelo Di Leo

Clinical trial

Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival

Jung Ah Lee, Kwan-Il Kim, Jeoung Won Bae, Young-Hoon Jung, Hyonggin An, Eun Sook Lee

Clinical trial

DNA repair signature is associated with anthracycline response in triple negative breast cancer patients

A. A. Rodriguez, A. Makris, M. F. Wu, M. Rimawi, A. Froehlich, B. Dave, S. G. Hilsenbeck, G. C. Chamness, M. T. Lewis, L. E. Dobrolecki, D. Jain, S. Sahoo, C. K. Osborne, J. C. Chang

Epidemiology

Associations between XPD polymorphisms and risk of breast cancer: a meta-analysis

Zheng Jiang, Chunxiang Li, Ye Xu, Sanjun Cai, Xishan Wang

Epidemiology

XRCC2 Arg188His polymorphism is not directly associated with breast cancer risk: evidence from 37,369 subjects

Ke-Da Yu, Ao-Xiang Chen, Li-Xin Qiu, Lei Fan, Chen Yang, Zhi-Ming Shao

Epidemiology

The association between ERCC2 Asp312Asn polymorphism and breast cancer risk: a meta-analysis involving 22,766 subjects

Lei Yao, Li-Xin Qiu, Lu Yu, Zhen Yang, Xia-Jia Yu, Yang Zhong, Xi-Chun Hu, Long Yu

Epidemiology

Global breast cancer seasonality

Eun-Young Oh, Christine Ansell, Hamayun Nawaz, Chul-Ho Yang, Patricia A. Wood, William J. M. Hrushesky

Epidemiology

Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer

Gretchen L. Gierach, Jennifer T. Loud, Catherine K. Chow, Sheila A. Prindiville, Jennifer Eng-Wong, Peter W. Soballe, Claudia Giambartolomei, Phuong L. Mai, Claudia E. Galbo, Kathryn Nichols, Kathleen A. Calzone, Celine Vachon, Mitchell H. Gail, Mark H. Greene

Epidemiology

Population-based survival-cure analysis of ER-negative breast cancer

Lan Huang, Karen A. Johnson, Angela B. Mariotto, James J. Dignam, Eric J. Feuer

Epidemiology

COMT Val158Met polymorphism and breast cancer risk: evidence from 26 case–control studies

Haixia Ding, Yuanyuan Fu, Weixian Chen, Zhanwei Wang

Brief Report

Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells

Mahvash Zakikhani, Marie-José Blouin, Esther Piura, Michael N. Pollak

Brief Report

Comparative disease pattern of a patient with a novel BRCA2 truncation and knockout models for BRCA2

Josefa Salgado, Cristina Gutiérrez, Carmen Gil, Maitane Robles, Jesús García-Foncillas

Brief Report

Treatment of breast cancer through the application of irreversible electroporation using a novel minimally invasive single needle electrode

Robert E. Neal II, Ravi Singh, Heather C. Hatcher, Nancy D. Kock, Suzy V. Torti, Rafael V. Davalos

Brief Report

Adjuvant!© Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer

Robert J. Paridaens, Shari Gelber, Bernard F. Cole, Richard D. Gelber, Beat Thürlimann, Karen N. Price, Stig B. Holmberg, Diana Crivellari, Alan S. Coates, Aron Goldhirsch

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.